Notably, recent clinical evidence suggests that ERCC1 levels predict response to platinum-based therapies in non-small cells lung cancer [1,78-80], small cell lung cancer [81], esophageal cancer [82], head and neck cancer [83], bladder cancer [84] and testicular cancer[85]. The gene discussed is ERCC1; the disease is urinary bladder cancer.